[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335333-105":59,"doc-detail-335333-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","predictors-of-response-to-immunotherapy-in-colorectal-cancer","Predictors of response to immunotherapy in colorectal cancer","","Colorectal cancer (CRC) is a major cause of cancer-related deaths globally. While targeted therapies informed by KRAS, NRAS, and BRAF mutations have improved outcomes, personalized approaches remain limited. Immune checkpoint blockade benefits only a small CRC subset, mainly patients with deficient mismatch repair (dMMR) or high microsatellite instability (MSI). New evidence challenges the idea that CRC is immunologically inert, identifying immunogenic subsets with distinct lymphocytic infiltration patterns. The review emphasizes discovering additional biomarkers from the tumor microenvironment, genomics, and gut microbiota, including consensus molecular subtypes, to broaden effective immunotherapy selection and guide future studies toward a fuller immunological landscape.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/predictors-of-response-to-immunotherapy-in-colorectal-cancer/335333/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/predictors-of-response-to-immunotherapy-in-colorectal-cancer/335333.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is immunotherapy only effective in a small subset of colorectal cancer patients?","Question",{"text":112,"@type":113},"Immune checkpoint blockade has strong activity mainly in patients with deficient mismatch repair (dMMR) or high microsatellite instability (MSI), which represent a minority of CRC cases (about 5%).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which factors beyond dMMR and MSI are discussed as additional predictors?",{"text":117,"@type":113},"The review highlights additional biomarker sources including the tumor microenvironment (TME), genomic biomarkers, and biomarkers related to the gut microbiota.",{"name":119,"@type":110,"acceptedAnswer":120},"How do consensus molecular subtypes help with patient selection?",{"text":121,"@type":113},"Consensus molecular subtypes (CMSs) support identifying CRC patients with immunogenic biology, going beyond reliance on a single biomarker to better match immunotherapy response potential.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335333,1790822809,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Predictors of response to immunotherapy in colorectal cancer  \nJaime González-Montero1,2,, Carlos I. Rojas1, Mauricio Burotto1,*,  \n1 Bradford Hill Clinical Research Center, Santiago 8420383, Chile,  \n2 Basic and Clinical Oncology Department, University of Chile, Santiago 838045, Chile  \n* Corresponding author: Mauricio Burotto, MD, Bradford Hill Clinical Research Center, Palestina (Ex Manzano) 343/377, Fourth/Fifth Floor, Recoleta, Santiago, Chile ([mburotto@bh.cl](mburotto@bh.cl)) .  \nAbstract  \nColorectal cancer (CRC) is a major cause of cancer-related deaths globally. While treatment advancements have improved survival rates, primarily through targeted therapies based on KRAS, NRAS, and BRAF mutations, personalized treatment strategies for CRC remain limited. Immunotherapy, mainly immune checkpoint blockade, has shown efficacy in various cancers but is effective in only a small subset of patients with CRC with deficient mismatch repair (dMMR) proteins or high microsatellite instability (MSI) . Recent research has challenged the notion that CRC is immunologically inert, revealing subsets with high immunogenicity and diverse lymphocytic infiltration. Identifying precise biomarkers beyond dMMR and MSI is crucial to expanding immunotherapy benefits. Hence, exploration has extended to various biomarker sources, such as the tumor microenvironment, genomic markers, and gut microbiota. Recent studies have introduced a novel classification system, consensus molecular subtypes, that aids in identifying patients with CRC with an immunogenic profile. These findings underscore the necessity of moving beyond single biomarkers and toward a comprehensive understanding of the immunological landscape in CRC, facilitating the development of more effective, personalized therapies.  \nKey words: colorectal cancer; immunotherapy; immune checkpoint blockade; consensus molecular subtypes; Immunoscore.  \nImplications for practice  \nExploring new therapeutic strategies for patients with colorectal cancer is of utmost importance. Immunotherapy emerges as a promising avenue, albeit its efficacy is predominantly acknowledged in patients exhibiting microsatellite instability or deficient mismatch repair proteins. Delving into additional biomarkers holds the potential to widen the pool of patients poised to derive benefits from immunotherapy. Moreover, a comprehensive molecular classification into consensus subtypes could usher in novel perspectives, transcending the conventional “one biomarker, one treatment” paradigm towards an approach that discerns unique molecular profiles. This review comprehensively addresses the most important biomarkers aiding in the refined selection of patients likely to benefit from immunotherapy and their clinical implications, while also underscoring the significance of directing future studies towards consensus molecular subtype classification.  \nIntroduction  \nColorectal cancer (CRC) is emerging as the leading cause of cancer mortality in Western countries. Modern chemotherapy and targeted therapy regimens have significantly improved patient survival based on the determination of the KRAS, NRAS, and BRAF mutation status.1 While progress has been made, gaps remain regarding the development of more personalized treatment approaches for patients with CRC.2 Immunotherapy with immune checkpoint blockade (ICB) has been established as a first-line treatment for various tumors. However, its impact on CRC treatment has been observed only in a small group of patients, primarily those with alterationsin deficient mismatch repair (dMMR) proteins or high microsatellite instability (MSI), who represent a minority of cases (approximately 5%).3 Previously, CRC cancer was considered to have poor immune infiltration and would be difficult to  \ntreat via immunotherapy. However, recent research has found that some CRC subtypes are highly immunogenic and exhibit diverse lymphocytic infiltration profiles. This suggests that more patients with ","cbCaiaRVWXl51R1w","https://ap.wps.com/l/cbCaiaRVWXl51R1w","pdf",5442575,"English","# Abstract\n# Implications for practice\n# Introduction\n# Predictors of response to immunotherapy in colorectal cancer","[{\"question\":\"Why is immunotherapy only effective in a small subset of colorectal cancer patients?\",\"answer\":\"Immune checkpoint blockade has strong activity mainly in patients with deficient mismatch repair (dMMR) or high microsatellite instability (MSI), which represent a minority of CRC cases (about 5%).\"},{\"question\":\"Which factors beyond dMMR and MSI are discussed as additional predictors?\",\"answer\":\"The review highlights additional biomarker sources including the tumor microenvironment (TME), genomic biomarkers, and biomarkers related to the gut microbiota.\"},{\"question\":\"How do consensus molecular subtypes help with patient selection?\",\"answer\":\"Consensus molecular subtypes (CMSs) support identifying CRC patients with immunogenic biology, going beyond reliance on a single biomarker to better match immunotherapy response potential.\"}]","Predictors of response to immunotherapy in colorectal cancer | PDF",1790010575,23]